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Dear Sir,
There is ample evidence that excess plas-
ma parathyroid hormone concentrations
(iPTH), especially in the presence of histo-
logical ostitis fibrosa, are associated with
worsening of anemia or resistance to the
action of erythropoietin. This may be coun-
teracted either by treatment with active
forms of vitamin D3 or by parathyroidecto-
my. The mechanisms involved in the com-
plex relationship between the autonomous
parathyroid glands and erythropoiesis are
not fully understood. The early response to
surgery or medical therapy suggests direct
effects on hematopoiesis such as suppression
of endogenous erythropoietin secretion, in-
hibition of bone marrow erythroid progeni-
tors or red cell survival. The continuous im-
provement of anemia may be further ex-
plained by decreased bone marrow fibrosis.
However, data regarding the operating fac-
tors are conflicting [1]. Inflammatory cyto-
kines such as interleukin-6 (IL-6) block
erythropoiesis by their effects on the devel-
opment of erythroblasts [2] and thereby ane-
mia and responsiveness to erythropoietin.
The question whether parathyroid hormone
excess affects synthesis of proinflammatory
cytokines remains unanswered.
We prospectively examined the effects of
parathyroidectomy on IL-6 levels, hemoglo-
bin concentrations and epoietin dose in 9
anemic patients with end-stage renal disease
(5 patients on CAPD, 4 patients on hemodi-
alysis) and severe secondary hyperparathy-
roidism. There were 5 men and 4 women,
aged 28–63 years, and the duration on dialy-
sis before surgery was 38–184 months (mean
85). The cause of end-stage renal disease was
chronic glomerulonephritis in 6 patients,
chronic tubulointerstitial nephritis in 2 pa-
tients and polycystic kidney disease in 1
patient. None of the patients had absolute or
relative iron deficiency, infection, inflam-
matory disorders, malignancy, occult gas-
trointestinal blood loss, aluminium toxicity
or was taking drugs known to interfere with
erythropoiesis. They all had normal vitamin
B12 and folic acid levels, and weekly Kt/V of
at least 3.6 for hemodialysis and 2.1 for
CAPD. The diagnosis of severe secondary
hyperparathyroidism was made on the basis
of biochemical, histological (bone biopsy),
radiological and clinical parameters. Blood
samples for determinations of iPTH and
other chemical parameters, serum IL-6 lev-
els, and hemoglobin concentrations were
drawn prior to surgery (within 1 week) and
6 months after surgery.
Parathyroidectomy (total parathyroidec-
tomy with a forearm transplant) resulted in
each patient in a normalization of excess
parathyroid hormone concentration, hyper-
calcemia (2.9 B 0.1 vs. 2.4 B 0.1 mmol/l),
hyperphosphatemia (6.5 B 0.5 vs. 3.4 B
0.5 mg/dl) and alkaline phosphatase (261 B
22 vs. 153 B 18 U/l). Compared to pre-
operative values, the postoperative epoie-
tin doses were significantly lower, although
Table 1. Effect of parathyroidectomy on
responsiveness to epoietin therapy in 9 ure-
mic patients
Parathyroidectomy
prior post
1,582B633 27B9*
IL-6, pg/ml 54B18 12B5*
CRP, mg/dl 1.3B0.2 0.2B0.1*
Hb, g/dl 9.2B0.4 10.8B0.4*
EPO dose,
U/kg/week 151B35 61B28*
* p ! 0.05 vs. preoperative values.
postoperative hemoglobin levels were signif-
icantly higher than corresponding levels be-
fore surgical therapy. Parathyroidectomy
was also associated with a fall in elevated IL-
6 values towards values usually observed in
chronic hemodialysis patients. Furthermore,
successfully treated patients had significant-
ly lower CRP values (table 1).
The worsening of anemia and the resis-
tance to erythropoietin characterizing severe
secondary hyperparathyroidism are caused
not by a single pathogenetic mechanism, but
may involve a number of factors operating
simultaneously at different stages of the de-
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velopment of parathyroid gland hyperplasia.
The present data disclose a previously un-
described link between excess parathyroid
hormone and erythropoiesis in hyperpara-
thyroidism secondary to end-stage renal dis-
ease. Circulating IL-6 levels were found to be
increased in our patients with severe second-
ary hyperparathyroidism as well as in 86 ure-
mic patients with different degrees of renal
osteodystrophy published by Montalban et
al. [3]. The authors of the latter series found
a strong correlation (r = 0.71) between iPTH
concentrations and corresponding IL-6 lev-
els in their 15 patients with severe secondary
hyperparathyroidism (iPTH 1250 pg/ml).
Goicoechea et al. [4] described a positive
correlation between IL-6 or TNF-· values
and erythropoietin doses in hemodialysis pa-
tients, but did not analyze the response to
epoietin dose in relation to the severity of
secondary hyperparathyroidism. Surgical
treatment of our patients with secondary hy-
perparathyroidism or successful parathyroid
adenomectomy of patients with primary hy-
perparathyroidism [5], resulted in a fall of
elevated IL-6 levels into the normal range.
Vitamin D3 metabolites have shown to sup-
press elevated IL-6 levels in diseased states
[6]. Whether the beneficial effects of active
vitamin D3 on anemia in patients with sec-
ondary hyperparathyroidism solely reflect
the correction of excess parathyroid hor-
mone secretion or, in addition, may also cor-
rect PTH or hypercalcemia-induced alter-
ations in cytokine synthesis, remains to be
shown.
In summary, severe secondary hyper-
parathyroidism represents an important fac-
tor affecting the pathogenesis of anemia in
uremic patients and is considered a revers-
ible cause of resistance to recombinant hu-
man erythropoietin therapy. The complex
relationship between excess parathyroid hor-
mone and erythropoiesis seems to involve
alterations of the synthesis of proinflamma-
tory cytokines.
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